Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer

被引:11
作者
Jaradat, Sara K. [1 ]
Ayoub, Nehad M. [1 ]
Al Sharie, Ahmed H. [2 ]
Aldaod, Julia M. [1 ]
机构
[1] Jordan Univ Sci & Technol JUST, Fac Pharm, Dept Clin Pharm, POB 3030, Irbid 22110, Jordan
[2] Jordan Univ Sci & Technol JUST, Fac Med, Dept Pathol & Microbiol, Irbid, Jordan
关键词
triple-negative breast cancer; receptor tyrosine kinases; small-molecule inhibitors; EGFR; MET; AXL; GROWTH-FACTOR RECEPTOR; POTENTIAL THERAPEUTIC TARGET; FACTOR-I RECEPTOR; GENE COPY NUMBER; CELL LUNG-CANCER; C-KIT; BIOLOGICAL SUBTYPES; CABOZANTINIB XL184; INHIBITS GROWTH; DOWN-REGULATION;
D O I
10.1177/15330338241234780
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Triple-negative breast cancer (TNBC) comprises a group of aggressive and heterogeneous breast carcinoma. Chemotherapy is the mainstay for the treatment of triple-negative tumors. Nevertheless, the success of chemotherapeutic treatments is limited by their toxicity and development of acquired resistance leading to therapeutic failure and tumor relapse. Hence, there is an urgent need to explore novel targeted therapies for TNBC. Receptor tyrosine kinases (RTKs) are a family of transmembrane receptors that are key regulators of intracellular signaling pathways controlling cell proliferation, differentiation, survival, and motility. Aberrant activity and/or expression of several types of RTKs have been strongly connected to tumorigenesis. RTKs are frequently overexpressed and/or deregulated in triple-negative breast tumors and are further associated with tumor progression and reduced survival in patients. Therefore, targeting RTKs could be an appealing therapeutic strategy for the treatment of TNBC. This review summarizes the current evidence regarding the antitumor activity of RTK inhibitors in preclinical models of TNBC. The review also provides insights into the clinical trials evaluating the use of RTK inhibitors for the treatment of patients with TNBC.
引用
收藏
页数:20
相关论文
共 183 条
[1]   Identification of a Triple Drug Combination That Is Synergistically Cytotoxic for Triple-Negative Breast Cancer Cells Using a Novel Combination Discovery Approach [J].
Ahmad, Syed ;
He, Qingping ;
Williams, Kevin P. ;
Scott, John E. .
SLAS DISCOVERY, 2020, 25 (08) :923-938
[2]  
Ahmed R, 2016, JCPSP-J COLL PHYSICI, V26, P570, DOI 2372
[3]   Metastatic and triple-negative breast cancer: challenges and treatment options [J].
Al-Mahmood, Sumayah ;
Sapiezynski, Justin ;
Garbuzenko, Olga B. ;
Minko, Tamara .
DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2018, 8 (05) :1483-1507
[4]   A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer [J].
AL-Tweigeri, Taher ;
AlSayed, Adher ;
Alawadi, Shafika ;
Ibrahim, Mohamed ;
Ashour, Wafaa ;
Jaafar, Hassan ;
Abulkhair, Omalkhair ;
AL-Abdulkarim, Huda ;
Khalid, Hassan ;
Ajarim, Dahish .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (01) :147-153
[5]   Basal-Like and Triple-Negative Breast Cancers Searching for Positives Among Many Negatives [J].
Alluri, Prasanna ;
Newman, Lisa A. .
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 23 (03) :567-+
[6]   Current and future burden of breast cancer: Global statistics for 2020 and 2040 [J].
Arnold, Melina ;
Morgan, Eileen ;
Rumgay, Harriet ;
Mafra, Allini ;
Singh, Deependra ;
Laversanne, Mathieu ;
Vignat, Jerome ;
Gralow, Julie R. ;
Cardoso, Fatima ;
Siesling, Sabine ;
Soerjomataram, Isabelle .
BREAST, 2022, 66 :15-23
[7]   ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics [J].
Arteaga, Carlos L. ;
Engelman, Jeffrey A. .
CANCER CELL, 2014, 25 (03) :282-303
[8]   Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies [J].
Ayoub, Nehad M. ;
Ibrahim, Dalia R. ;
Alkhalifa, Amer E. .
MEDICAL ONCOLOGY, 2021, 38 (12)
[9]   Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents [J].
Ayoub, Nehad M. ;
Al-Shami, Kamal M. ;
Alqudah, Mohammad A. ;
Mhaidat, Nizar M. .
ONCOTARGETS AND THERAPY, 2017, 10 :4869-4883
[10]   Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line [J].
Ayub, Ayunadirah ;
Yip, Wai Kien ;
Seow, Heng Fong .
BIOMEDICINE & PHARMACOTHERAPY, 2015, 75 :40-50